Enterprise Value
2.512B
Cash
698.8M
Avg Qtr Burn
-32.8M
Short % of Float
15.89%
Insider Ownership
1.01%
Institutional Own.
99.14%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Darovasertib (IDE196) (PKC Inhibitor) + crizotinib Details Solid tumor/s, Metastatic uveal melanoma, Cancer | Phase 2/3 Data readout | |
IDE397 (MAT2A) Details Solid tumor/s, Cancer, Non-small cell lung carcinoma, Bladder cancer | Phase 2 Data readout | |
Darovasertib Details Cancer, Solid tumor/s, Uveal melanoma | Phase 2 Data readout | |
Darovasertib Details Cancer, Ocular melanoma | Phase 2 Update | |
Darovasertib (IDE196) (PKC Inhibitor) + crizotinib Details Solid tumor/s, Metastatic uveal melanoma, Cancer, Cutaneous Melanoma | Phase 1/2 Data readout | |
GSK101 (IDE705) + niraparib Details Cancer, Solid tumor/s | Phase 1/2 Data readout | |
IDE397 (MAT2A) +/- AMG 193 Details Cancer, Solid tumor/s, Non-small cell lung carcinoma | Phase 1/2 Data readout | |
IDE397 (MAT2A) + Trodelvy Details Solid tumor/s, Cancer, Bladder cancer | Phase 1 Data readout | |
IDE161 Details Solid tumor/s, Cancer, ER+/HER2- breast cancer, Ovarian cancer, Endometrial cancer | Phase 1 Data readout |